| Professional Services Industry | Industrials Sector | Mr. Rahul Franklin Guha CEO | MSE Exchange | Y8T01E103 CUSIP |
| India Country | 1,822 Employees | 23 Jun 2026 Last Dividend | 28 Nov 2025 Last Split | - IPO Date |
Thyrocare Technologies Limited, established in 1996 and headquartered in Navi Mumbai, India, stands as a pivotal provider of diagnostic testing services across the nation. Catering to patients, laboratories, and hospitals, Thyrocare operates through three main segments: Diagnostic Testing Services, Imaging Services, and Others. The company has carved a niche in the realm of medical diagnostics by emphasizing early detection and management of an array of disorders and diseases. These include, but are not limited to, thyroid-related disorders, growth and metabolism issues, auto-immunity diseases, diabetes, anaemia, cardiovascular conditions, infertility issues, COVID, and various infectious diseases. As a subsidiary of Docon Technologies Private Limited, Thyrocare Technologies Limited continues to advance in its mission to offer comprehensive and quality diagnostic solutions.
Thyrocare Technologies Limited's portfolio encompasses a broad spectrum of products and services aimed at bolstering healthcare diagnostics: